Hypnotic drug use among 0–17 year olds during 2004–2011: A nationwide prescription database study

Scandinavian Journal of Public Health

Volumn 40, Issue 8, 2012, Pages 704-711

  Hartz, Ingeborg ^a   Furu, Kari ^b   Bratlid, Trond ^c   Handal, Marte ^b   Skurtveit, Svetlana ^d  

^a INLAND NORWAY UNIVERSITY OF APPLIED SCIENCES   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

adolescent; children; Hypnotic drugs; longitudinal study; Norway; pharmacoepidemiology; prescription database

Indexed keywords

HYPNOTIC SEDATIVE AGENT; MELATONIN;

ADOLESCENT; ARTICLE; CHILD; CHRONIC DISEASE; DRUG UTILIZATION; FACTUAL DATABASE; FEMALE; HUMAN; INFANT; MALE; NORWAY; PRESCHOOL CHILD; PRESCRIPTION; PREVALENCE; STATISTICS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; INFANT; MALE; MELATONIN; NORWAY; PREVALENCE;

EID: 84870577694     PISSN: 14034948     EISSN: 16511905     Source Type: Journal    
DOI: 10.1177/1403494812464446     Document Type: Article

References (30)

1. Johnson E.O. Roth T. Schultz L. Breslau N. Epidemiology of DSM-IV insomnia in adolescence: lifetime prevalence, chronicity, and an emergent gender difference. Pediatrics 2006;117:e247–e256.
2. Zito J.M. Safer D.J. Berg L.T. et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health 2008;2:26.
3. Bonati M. Clavenna A. The epidemiology of psychotropic drug use in children and adolescents. Int Rev Psychiatry 2005;17:181–8.
4. Hsia Y. Maclennan K. Rise in psychotropic drug prescribing in children and adolescents during 1992–2001: a population-based study in the UK. Eur J Epidemiol 2009;24:211–6.
5. Skurtveit S. Rosvold E.O. Furu K. Use of psychotropic drugs in an urban adolescent population: the impact of health-related variables, lifestyle and sociodemographic factors–The Oslo Health Study 2000–2001. Pharmacoepidemiol Drug Saf 2005;14:277–83.
6. Slordal L. Bramness J.G. Is alimemazine a suitable sleeping agent for children? Tidsskrift for den Norske laegeforening 2008;128:2194–6.
7. Kjosavik S.R. Ruths S. Hunskaar S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 2009;18:572–8.
8. Steffenak A.K.M. Nordstrøm G. Wilde-Larsson B. et al. Increase in psychotropic drug use betweeb 2006 and 2010 among adolescents in Norway: a nationwide prescription database study. Clin Epidemiol 2012;4:225–31.
9. The Norwegian Prescription Database, National Institute of Public Health, http://www.fhi.no/eway/default.aspx?pid=233&trg=MainArea_5661&MainArea_5661=5565:0:15,3791:1:0:0:::0:0&MainLeft_5565=5544:50553::1:5569:10:::0:0 (accessed 1 September 2012).
10. Hansen E.H. Holstein B.E. Due P. Time trends in medicine use among adolescents in industrialised countries. Eur J Pub Health 2003;13:43.
11. Holstein B. Andersen A. Due P. et al. Children's and adolescent's use of medicine for aches and psychological problems: secular trends from 1988 to 2006. Ugeskrift for laeger 2009;171:24–28.
12. Pallesen S. Hetland J. Sivertsen B. et al. Time trends in sleep-onset difficulties among Norwegian adolescents: 1983–2005. Scand J Pub Health 2008;36:889–95.
13. Sivertsen B. Hysing M. Elgen I. et al. Chronicity of sleep problems in children with chronic illness: a longitudinal population-based study. Child Adolesc Psychiatry Ment Health 2009;3:22.
14. Ramchandani P. Wiggs L. Webb V. et al. A systematic review of treatments for settling problems and night waking in young children. BMJ 2000;320:209–13.
15. Cortese S. Konofal E. Yateman N. et al. Sleep and alertness in children with attention-deficit/hyperactivity disorder: a systematic review of the literature. Sleep 2006; 29:504–11.
16. Rønning M. Berg C. Furu K. et al. The Norwegian Prescription Database 2004–2008. Report 2009:2, Norwegian Institute of Public Health, 2009.
17. Zoega H. Furu K. Halldorsson M. et al. Use of ADHD drugs in the Nordic countries: a population-based comparison study. Acta Psychiatr Scand 2011;123:360–7.
18. Buscemi N. Vandermeer B. Hooton N. et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Int Med 2005;20:1151–8.
19. Buscemi N. Vandermeer B. Hooton N. et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006;332:385–93.
20. European Medicines Agency. Summary of product characteristics (SPC) for Circadin (melatonin), at: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000695/human_med_000701.jsp&mid=WC0b01ac058001d124 (accessed 10 September 2012).
21. Zhdanova I.V. Melatonin as a hypnotic: pro. Sleep Med Rev 2005;9:51–65.
22. Padfield N.L. Twohig M.M. Fraser A.C. Temazepam and trimeprazine compared with placebo as premedication in children. An investigation extended into the first 2 weeks at home. Br J Anaesth 1986;58:487–93.
23. Mann N.P. Trimeprazine and respiratory depression. Arch Dis Child 1981;56:481–2.
24. France K.G. Blampied N.M. Wilkinson P. Treatment of infant sleep disturbance by trimeprazine in combination with extinction. J Dev Behav Pediatr 1991;12:308–14.
25. Lissauer T. Clayden G. Illustrated textbook of peadiatrics. Edinburgh: Mosby, 2011.
26. Holstein B.E. Holme Hansen E. Due P. et al. Self-reported medicine use among 11- to 15-year-old girls and boys in Denmark 1988–1998. Scand J Pub Health 2003;31:334–41.
27. Hansen E.H. Holstein B.E. Due P. et al. International survey of self-reported medicine use among adolescents. Ann Pharmacother 2003;37:361–6.
28. Hansen D.L. Hansen E.H. Holstein B.E. Young women's use of medicines: autonomy and positioning in relation to family and peer norms. Health (London) 2009;13:467–85.
29. Carskadon M.A. Vieira C. Acebo C. Association between puberty and delayed phase preference. Sleep 1993;16:258–62.
30. Kelder S.H. Perry C.L. Klepp K.I. et al. Longitudinal tracking of adolescent smoking, physical activity, and food choice behaviors. Am J Public Health 1994;84:1121–6.